Healthcare entity
market-trends is the sole category represented across all 1 tracked stories. NeurAxis, Inc. is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Their average consequence score of 5 runs below the beat's 6.3 for that window.
Last mentioned: Mar 20, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
market-trends is the sole category represented across all 1 tracked stories. NeurAxis, Inc. is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Their average consequence score of 5 runs below the beat's 6.3 for that window. Source depth averages 3 original sources per story, versus 2.9 across the same-window beat baseline. We currently track 1 Healthcare story that mention IB-Stim, all published on March 20, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 23 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering IB-Stim. Shared-story counts are live from our verified record — not editorial picks.
Relmada Therapeutics and NeurAxis reported Q4 2025 results, highlighting a strategic shift toward late-stage clinical readouts and expanded commercial coverage for CNS therapies. Both companies are positioning themselves as leaders in non-traditional treatments for depression and pediatric pain, respectively.
Source: seekingalpha.com · insidermonkey.com
IB-Stim is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
